GAITHERSBURG, Md., Oct. 13 /PRNewswire-FirstCall/ -- Iomai Corporation today announced that Stanley C. Erck, the company's president and chief executive officer, is scheduled to present at the 2006 BioInvestor Forum on Wednesday, October 18 at 4:20 p.m. PDT.
The conference will be held at the Palace Hotel in San Francisco.
To access the live audio webcast or the subsequent archived recording, log on to the Investor Relations section on the Overview page of the Iomai website at http://www.iomai.com/. Please connect to Iomai's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.
ABOUT IOMAI CORPORATION:
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent E. coli-related travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com/.
Some matters discussed in this press release constitute "forward-looking statements" that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements about Iomai's ability to stimulate stronger immune responses, the ability of Iomai's patches to expand vaccine markets, and the benefits of its patch technology. Applicable risks and uncertainties include, among others, that results in future trials may not replicate results seen in prior trials; that Iomai may be unable to obtain the regulatory approvals necessary to conduct additional clinical trials or to market any product candidates for its product candidates; that development costs may exceed expectations; that Iomai may fail to adequately protect its intellectual property or may be determined to infringe on the intellectual property of others; and the risks identified in its filings with the Securities and Exchange Commission, which are available at http://www.sec.gov/. Iomai cautions investors and others not to place undue reliance on the forward-looking statements contained in this press release.
